Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lisa-Jane K Graham"'
Autor:
Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, Siavash Foroughi, Stephen Brown, Lisa-Jane K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104738- (2023)
Summary: Background: Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for optimisi
Externí odkaz:
https://doaj.org/article/868bde2315c940f2aff0e43052a1b905
Autor:
Zhixin Zhao, Edmond M. Kwan, Pan Du, Manish Kohli, Arun Azad, Heidi Fettke, Winston Tan, Tiantian Zheng, Jianjun Yu, Maria Docanto, Christine Hauser, Patricia Bukczynska, Kemin Zhou, Xiaohong Wang, Chao Dai, Shidong Jia, Lisa-Jane K Graham, Nicole Ng, Siavash Foroughi, Kate L. Mahon, Lisa G. Horvath
Publikováno v:
JCO Precis Oncol
PURPOSE Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA (cfDNA) has proven to be challenging. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ee7982a95bf2ec733ddc8190b79ad7
https://doi.org/10.1200/po.20.00424
https://doi.org/10.1200/po.20.00424
Autor:
Edmond M. Kwan, Kate L. Mahon, Tilman Todenhöfer, Phillip Parente, Sarah Azer, Patricia Bukczynska, Ian D. Davis, Lisi Elizabeth Lim, Niranjan J. Sathianathen, Lisa G. Horvath, Lisa-Jane K Graham, Maria Docanto, Nicole Ng, Heidi Fettke, Christine Hauser, Anne-Maree Haynes, Carmel Pezaro, Siavash Foroughi, Megan Crumbaker, Sarah Q. To, Arun Azad, Anthony M. Joshua, Andrew Mant, Eva Segelov
Publikováno v:
Translational Andrology and Urology. 10:1688-1699
Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00b82b83eb05aafbdca2c1a33f20b3bf
https://doi.org/10.21037/tau-20-1444
https://doi.org/10.21037/tau-20-1444
Autor:
Tilman Todenhöfer, Lisa G. Horvath, Andrew Mant, Maria Docanto, Edmond M. Kwan, Nicole Ng, Stefano Mangiola, Kate L. Mahon, Ian D. Davis, Sarah Q. To, David Pook, Lisa Jane K. Graham, Arun Azad, Heidi Fettke, Carmel Pezaro, Phillip Parente, Patricia Bukczynska, Eva Segelov
Publikováno v:
European Urology Focus. 7:63-70
The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb31148479814a82d3266e533c52e3e
https://doi.org/10.1016/j.euf.2019.04.020
https://doi.org/10.1016/j.euf.2019.04.020
Autor:
Edmond M, Kwan, Heidi, Fettke, Megan, Crumbaker, Maria M, Docanto, Sarah Q, To, Patricia, Bukczynska, Andrew, Mant, Nicole, Ng, Siavash, Foroughi, Lisa-Jane K, Graham, Anne-Maree, Haynes, Sarah, Azer, Lisi Elizabeth, Lim, Eva, Segelov, Kate, Mahon, Ian D, Davis, Phillip, Parente, Carmel, Pezaro, Tilman, Todenhöfer, Niranjan, Sathianathen, Christine, Hauser, Lisa G, Horvath, Anthony M, Joshua, Arun A, Azad
Publikováno v:
Transl Androl Urol
BACKGROUND: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4f0bace130d69e45160d4caad46e98cc
https://pubmed.ncbi.nlm.nih.gov/33968657
https://pubmed.ncbi.nlm.nih.gov/33968657
Autor:
Heidi Fettke, Christine Hauser, Edmond Michael Kwan, Chao Dai, Tiantian Zheng, Amy Wang, Winston Tan, Pan Du, Nicole Ng, Patricia Bukczynska, Siavash Foroughi, Lisa-Jane K. Graham, Lisa Horvath, Kate Lynette Mahon, Shidong Jia, Manish Kohli, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 40:153-153
153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports. Whether DDR alterations are predictive of outcomes with therapeutic agents other than PARP inhibitors in mCRPC is also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02884b25947e038d39e020e7f6518c70
https://doi.org/10.1200/jco.2022.40.6_suppl.153
https://doi.org/10.1200/jco.2022.40.6_suppl.153
Autor:
Andrea Knox, Heidi Fettke, Christine Hauser, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K. Graham, Kate Lynette Mahon, Winston Tan, Tiantian Zheng, Chao Dai, Pan Du, Shidong Jia, Lisa Horvath, Manish Kohli, Arun Azad, Edmond Michael Kwan, Amy Wang
Publikováno v:
Journal of Clinical Oncology. 40:150-150
150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is of increasing relevance. However, the influence of age on the detection of relevant genomic alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37e65636154f765d52f79d055a77b2bc
https://doi.org/10.1200/jco.2022.40.6_suppl.150
https://doi.org/10.1200/jco.2022.40.6_suppl.150
Autor:
Luciano G. Martelotto, Maria Docanto, Lisa Jane K. Graham, Edmond M. Kwan, Patricia Bukczynska, Sarah Q. To, Heidi Fettke, Tilman Todenhöfer, Arun Azad, Andrew Mant, Nicole Ng, Carmel Pezaro, Lisa G. Horvath, Kate L. Mahon, Phillip Parente
Publikováno v:
European Urology. 73:818-821
In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72fa4f2fbf1d3ad2dab93c5dea5ffdf
https://doi.org/10.1016/j.eururo.2018.01.007
https://doi.org/10.1016/j.eururo.2018.01.007
Autor:
Lisa Jane K. Graham, Manish Kohli, Heidi Fettke, Pan Du, Arun Azad, Patricia Bukczynska, Zhixin Zhao, Shidong Jia, Jianjun Yu, Maria Docanto, Edmond M. Kwan, Kate L. Mahon, Tiantian Zheng, Christine Hauser, Winston Tan, Kemin Zhou, Lisa G. Horvath, Nicole Ng, Yong Huang, Xiaohong Wang
Publikováno v:
Eur Urol
Background The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and RNA may identify key predictive and/or prognostic biomarkers in the conte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f202bc083975a07a61b62e7b7d9b091
https://pubmed.ncbi.nlm.nih.gov/32376139
https://pubmed.ncbi.nlm.nih.gov/32376139
Autor:
Kate L. Mahon, Arun Azad, Manish Kohli, Feng Xie, Jianjun Yu, Edmond M. Kwan, Christine Hauser, Lisa G. Horvath, Peter Du, Patricia Bukczynska, Shidong Jia, Kemin Zhou, Winston Tan, Zhixin Zhao, Nicole Ng, Heidi Fettke, Xiaohong Wang, Chao Dai, Lisa-Jane K Graham
Publikováno v:
Journal of Clinical Oncology. 38:176-176
176 Background: Multiple tumour tissue studies have demonstrated the prognostic utility of CNVs in mCRPC. However, accurate assessment of CNVs in plasma cfDNA remains challenging, and prognostic significance has not been well characterized. Using a l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edad55ec1c6b59540f427454e6d4cad6
https://doi.org/10.1200/jco.2020.38.6_suppl.176
https://doi.org/10.1200/jco.2020.38.6_suppl.176